Back to School: How biopharma can reboot drug development. Access exclusive analysis here
GENT plans to submit a protocol amendment to FDA for an ongoing Phase III trial of defibrotide in order
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury